We’ve created a pipeline of novel vaccine and immunotherapy programs that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immune responses against a wide array of diseases. Our pipeline includes programs addressing herpes simplex virus-2 (HSV-2), pneumococcus, chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

from http://www.genocea.com

Research Grants 1 show all


$2.7M
2009

Publications 26 show all

  • 6
    Herpesvirus 2, Human/immunology
  • 4
    Herpes Genitalis/immunology
  • 4
    T-Lymphocytes/immunology
  • 3
    Antibodies, Viral/blood
  • 3
    Chlamydia trachomatis/immunology
  • 3
    Herpes Genitalis/therapy
  • 3
    Herpes Zoster Vaccine/immunology
  • 3
    Herpes Zoster/prevention & control
  • 3
    Herpesvirus 3, Human/immunology
  • 3
    Viral Vaccines/immunology

Patents 106show all

  • 45
    A61K - Preparations for medical, dental, or toilet purposes
  • 24
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 16
    C12N - Microorganisms or enzymes
  • 15
    C07K - Peptides
  • 8
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 8
    G01N - Investigating or analysing materials by determining their chemical or physical properties

Clinical Trials 10show all

6Phase 22Phase 1/Phase 21Phase 1

SEC Filings show all


76
8-K

18
10-Q

7
10-K

5
D

1
S-1

Contact Information

Cambridge, MA
United States

SEC Form D Funding Events

DateOfferedSoldType
2013-10-10$400,000$400,000Option to Acquire, Security to be Acquired
2013-07-02$30,500,000$30,500,000Equity
2011-01-03$35,099,999$35,099,999Equity
2009-02-25Unknown Unknown Other (Paper Filing)

Key Executives

  • George Siber
    Director
  • Dalton Einhorn
    Executive Officer, Director
  • Kevin Bitterman
    Director
  • Simeon George
    Director
  • Steve Hoffman
    Director
  • Robert Paull
    Director
  • Robert Farrell Jr.
    Executive Officer
  • Jessica Baker Flechtner
    Executive Officer
  • Paul Giannasca
    Executive Officer
  • William Clark
    Executive Officer
  • Asish Xavier
    Director
  • Stephen Hoffman
    Director
  • Robert E. Farrell Jr.
    Executive Officer
  • Seth Hetherington
    Executive Officer
  • Ravi Venkataramani
    Executive Officer
  • Katrine Bosley
    Director